Stay updated with breaking news from Hartmut Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of the
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022
Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study - News - PharmaTimes
Abivax’s COVID-19 study declared Research National Priority by French government Drug treatment is being investigated in high-risk COVID-19 patients Abivax’s COVID-19 study evaluating its anti-inflammatory candidate ABX464 has been deemed a ‘research national priority’ by a French government steering committee. The steering committee for therapeutic clinical trials and other research (CAPNET) was created by the French government to identify promising and impactful COVID-19 clinical trials. Those clinical trials, including Abivax’s study, that are declared to be a national priority ...